Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya(Houston Methodist), Carlos A. Ramos(Methodist Hospital)
Cited by 312
Related Papers
Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
|Journal of Clinical Investigation|2017|368
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
|Journal of Clinical Investigation|2016|280